Amant Frédéric, Coosemans An, Renard Vincent, Everaert Els, Vergote Ignace
Division of Gynecological Oncology, Department of Obstetrics and Gynecology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Int J Gynecol Cancer. 2009 Feb;19(2):245-8. doi: 10.1111/IGC.0b013e31819c0f59.
The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which 1 had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients. These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.
研究了ET - 743（曲贝替定；Yondelis）对先前接受过化疗的平滑肌肉瘤和未分化子宫肉瘤女性患者的临床影响。目前的数据显示，5例患者中有2例有临床获益，其中1例在9个月内出现部分缓解。将治疗结果与文献数据汇总后，计算出所有高级别子宫肉瘤患者中，13例患者中有5例（38%）有反应，7例（54%）有临床获益。仅考虑子宫平滑肌肉瘤时，11例患者中有5例（45%）有反应，7例（64%）有临床获益。这些关于ET - 743在子宫肉瘤患者中应用的结果支持开展更大规模的试验。
